BR112014019459A2 - proteínas de ligação à cdim e usos das mesmas - Google Patents

proteínas de ligação à cdim e usos das mesmas

Info

Publication number: BR112014019459A2
Authority: BR; Brazil
Prior art keywords: binding proteins; cdim binding; cdim; proteins; binding
Prior art date: 2012-02-08

Application number

BR112014019459A

Other languages

English (en)

Other versions

BR112014019459B1 (pt

BR112014019459A8 (pt

Inventor

A Keyt Bruce

M Bieber Marcia

M Bhat Neelirna

N H Teng Nelson

Original Assignee

Igm Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-02-08

Filing date

2013-02-08

Publication date

2017-06-27

2013-02-08 Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc

2017-06-27 Publication of BR112014019459A2 publication Critical patent/BR112014019459A2/pt

2023-01-10 Publication of BR112014019459A8 publication Critical patent/BR112014019459A8/pt

2023-04-18 Publication of BR112014019459B1 publication Critical patent/BR112014019459B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cell Biology (AREA)
Hematology (AREA)
Oncology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Transplantation (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BR112014019459-9A 2012-02-08 2013-02-08 Proteínas de ligação à cdim e usos das mesmas BR112014019459B1 (pt)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201261633330P	2012-02-08	2012-02-08
US61/633,330		2012-02-08
PCT/US2013/025430 WO2013120012A2 (en)	2012-02-08	2013-02-08	Cdim binding proteins and uses thereof

Publications (3)

Publication Number	Publication Date
BR112014019459A2 true BR112014019459A2 (pt)	2017-06-27
BR112014019459A8 BR112014019459A8 (pt)	2023-01-10
BR112014019459B1 BR112014019459B1 (pt)	2023-04-18

Family

ID=48045015

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR112014019459-9A BR112014019459B1 (pt)	2012-02-08	2013-02-08	Proteínas de ligação à cdim e usos das mesmas

Country Status (15)

Country	Link
US (1)	US9409976B2 (pt)
EP (1)	EP2812356B1 (pt)
JP (1)	JP6335796B2 (pt)
KR (1)	KR102102111B1 (pt)
CN (1)	CN104254544B (pt)
AU (1)	AU2013200903B2 (pt)
BR (1)	BR112014019459B1 (pt)
CA (1)	CA2863714C (pt)
DK (1)	DK2812356T3 (pt)
ES (1)	ES2735289T3 (pt)
HK (1)	HK1205136A1 (pt)
IN (1)	IN2014MN01781A (pt)
MX (1)	MX363819B (pt)
TW (1)	TWI606064B (pt)
WO (1)	WO2013120012A2 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105722855B (zh)	2013-09-05	2021-04-23	Igm生物科学股份有限公司	恒定链经修饰的双特异性五价和六价Ig-M抗体
CA2933960A1 (en) *	2013-12-17	2015-06-25	Aimm Therapeutics B.V.	Means and methods for counteracting myeloproliferative or lymphoproliferative disorders
WO2015120474A1 (en)	2014-02-10	2015-08-13	Igm Biosciences, Inc.	Iga multi-specific binding molecules
JP6744822B2 (ja)	2014-04-03	2020-08-19	アイジーエムバイオサイエンシズインコーポレイテッド	修飾ｊ鎖
CA2972990A1 (en)	2015-01-20	2016-07-28	Beatrice Tien-Yi WANG	Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
EP3265575B1 (en)	2015-03-04	2021-04-21	IGM Biosciences, Inc.	Cd20 binding molecules and uses thereof
EP3274051A4 (en)	2015-03-25	2018-08-22	IGM Biosciences A/S	Multi-valent hepatitis b virus antigen binding molecules and uses thereof
US10570191B2 (en)	2015-04-17	2020-02-25	Igm Biosciences, Inc.	Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CN108463472A (zh)	2015-09-30	2018-08-28	Igm生物科学有限公司	具有修饰的j-链的结合分子
WO2017059380A1 (en)	2015-09-30	2017-04-06	Igm Biosciences, Inc.	Binding molecules with modified j-chain
HUE055972T2 (hu)	2016-05-09	2022-01-28	Igm Biosciences Inc	Anti-PD-L1 antitestek
ES2821924T3 (es) *	2016-08-15	2021-04-28	Novartis Ag	Regímenes y métodos de tratamiento de la esclerosis múltiple utilizando ofatumumab
WO2018148447A1 (en) *	2017-02-08	2018-08-16	Adimab, Llc	Antibody heavy chain variable domains targeting the nkg2d receptor
JP2020506971A (ja)	2017-02-08	2020-03-05	ドラゴンフライセラピューティクス，インコーポレイテッド	ナチュラルキラー細胞の活性化のための多重特異性結合タンパク質およびがんを処置するためのその治療的使用
SG11201907646YA (en)	2017-02-20	2019-09-27	Dragonfly Therapeutics Inc	Proteins binding her2, nkg2d and cd16
KR102696143B1 (ko)	2017-04-07	2024-08-21	아이쥐엠 바이오사이언스 인코포레이티드	보체-의존성 세포용해 효과기 기능의 조정을 위한 변형된 인간 IgM 불변 영역
FI3749346T3 (fi)	2018-02-08	2024-09-04	Dragonfly Therapeutics Inc	Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät
SG11202008343YA (en)	2018-03-01	2020-09-29	Igm Biosciences Inc	IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE
SG11202105010UA (en) *	2018-11-16	2021-06-29	Memorial Sloan Kettering Cancer Center	Antibodies to mucin-16 and methods of use thereof
BR112022002780A2 (pt)	2019-08-15	2022-05-10	Igm Biosciences Inc	Moléculas de ligação multiméricas imunoestimulatórias
TW202241935A (zh)	2020-12-18	2022-11-01	美商世紀治療股份有限公司	具有可調適受體專一性之嵌合抗原受體系統
CN114181318B (zh) *	2021-11-08	2023-08-01	四川大学	一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4399216A (en)	1980-02-25	1983-08-16	The Trustees Of Columbia University	Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4740461A (en)	1983-12-27	1988-04-26	Genetics Institute, Inc.	Vectors and methods for transformation of eucaryotic cells
US4959455A (en)	1986-07-14	1990-09-25	Genetics Institute, Inc.	Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en)	1986-09-05	1993-09-21	The United States Of America As Represented By The Secretary Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en)	1986-09-05	1992-03-24	Gansow Otto A	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US4912040A (en)	1986-11-14	1990-03-27	Genetics Institute, Inc.	Eucaryotic expression system
DE3920358A1 (de) *	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5460785A (en)	1989-08-09	1995-10-24	Rhomed Incorporated	Direct labeling of antibodies and other protein with metal ions
US5124471A (en)	1990-03-26	1992-06-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Bifunctional dtpa-type ligand
AU3178993A (en)	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
US5521184A (en)	1992-04-03	1996-05-28	Ciba-Geigy Corporation	Pyrimidine derivatives and processes for the preparation thereof
US5417972A (en)	1993-08-02	1995-05-23	The Board Of Trustees Of The Leland Stanford Junior University	Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM
US6083903A (en)	1994-10-28	2000-07-04	Leukosite, Inc.	Boronic ester and acid compounds, synthesis and uses
US6312691B1 (en)	1996-01-26	2001-11-06	Jeffrey L. Browning	Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US6962979B1 (en)	1995-03-14	2005-11-08	Cohesion Technologies, Inc.	Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents
US5855911A (en)	1995-08-29	1999-01-05	Board Of Regents, The University Of Texas System	Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US6235883B1 (en) *	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
US6680335B2 (en)	1998-09-28	2004-01-20	Sugen, Inc.	Methods of modulating protein tyrosine kinase function with substituted indolinone compounds
IL148718A0 (en)	1999-09-17	2002-09-12	Abbott Gmbh & Co Kg	Pyrazolopyrimidines as therapeutic agents
US20020028178A1 (en)	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
WO2002096948A2 (en)	2001-01-29	2002-12-05	Idec Pharmaceuticals Corporation	Engineered tetravalent antibodies and methods of use
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6645974B2 (en)	2001-07-31	2003-11-11	Merck & Co., Inc.	Androgen receptor modulators and methods for use thereof
WO2003070752A2 (en) *	2002-02-20	2003-08-28	Dyax Corporation	Mhc-peptide complex binding ligands
US7485297B2 (en) *	2003-08-12	2009-02-03	Dyax Corp.	Method of inhibition of vascular development using an antibody
US20120237441A9 (en)	2003-11-05	2012-09-20	Bhat Neelima M	Enhanced b cell cytotoxicity of cdim binding antibody
EP1682179A4 (en)	2003-11-05	2008-09-03	Palingen Inc	INCREASED CYTOTOXICITY OF CDIM BINDING ANTIBODY AGAINST B LYMPHOCYTES
US8377435B2 (en) *	2004-11-05	2013-02-19	The Board Of Trustees Of The Leland Stanford Junior University	Antibody induced cell membrane wounding
DE602005027258D1 (de) *	2005-03-14	2011-05-12	Us Gov Health & Human Serv	Humane monoklonale antikörper gegen hendra- und nipah-viren
CA2623016A1 (en) *	2005-09-19	2007-03-29	Palingen, Inc.	Treatment of b cell diseases using anti-germline antibody binding agents
SG182985A1 (en) *	2007-04-02	2012-08-30	Amgen Fremont Inc	Anti-ige antibodies

2013
- 2013-02-08 DK DK13713588.5T patent/DK2812356T3/da active
- 2013-02-08 JP JP2014556751A patent/JP6335796B2/ja active Active
- 2013-02-08 TW TW102105337A patent/TWI606064B/zh active
- 2013-02-08 ES ES13713588T patent/ES2735289T3/es active Active
- 2013-02-08 AU AU2013200903A patent/AU2013200903B2/en active Active
- 2013-02-08 CN CN201380008515.XA patent/CN104254544B/zh active Active
- 2013-02-08 MX MX2014009628A patent/MX363819B/es active IP Right Grant
- 2013-02-08 WO PCT/US2013/025430 patent/WO2013120012A2/en active Application Filing
- 2013-02-08 CA CA2863714A patent/CA2863714C/en active Active
- 2013-02-08 EP EP13713588.5A patent/EP2812356B1/en active Active
- 2013-02-08 KR KR1020147025110A patent/KR102102111B1/ko active IP Right Grant
- 2013-02-08 IN IN1781MUN2014 patent/IN2014MN01781A/en unknown
- 2013-02-08 US US13/763,398 patent/US9409976B2/en active Active
- 2013-02-08 BR BR112014019459-9A patent/BR112014019459B1/pt active IP Right Grant
2015
- 2015-06-09 HK HK15105490.7A patent/HK1205136A1/xx unknown

Also Published As

Publication number	Publication date
KR102102111B1 (ko)	2020-04-20
MX363819B (es)	2019-04-03
CA2863714A1 (en)	2013-08-15
EP2812356A2 (en)	2014-12-17
TWI606064B (zh)	2017-11-21
BR112014019459B1 (pt)	2023-04-18
AU2013200903A1 (en)	2013-08-22
BR112014019459A8 (pt)	2023-01-10
IN2014MN01781A (pt)	2015-07-03
EP2812356B1 (en)	2019-03-27
MX2014009628A (es)	2015-03-19
US20140044739A1 (en)	2014-02-13
DK2812356T3 (da)	2019-07-08
ES2735289T3 (es)	2019-12-17
WO2013120012A3 (en)	2013-11-07
TW201345921A (zh)	2013-11-16
WO2013120012A2 (en)	2013-08-15
JP6335796B2 (ja)	2018-06-06
JP2015511817A (ja)	2015-04-23
US9409976B2 (en)	2016-08-09
KR20150001728A (ko)	2015-01-06
CA2863714C (en)	2022-07-05
HK1205136A1 (en)	2015-12-11
CN104254544A (zh)	2014-12-31
CN104254544B (zh)	2017-04-26
AU2013200903B2 (en)	2015-05-14

Publication	Publication Date	Title
BR112014019459A2 (pt)	2017-06-27	proteínas de ligação à cdim e usos das mesmas
IL286784A (en)	2021-10-31	Compositions of protein and antibody
BR112014020304A8 (pt)	2018-01-16	terapêutica para ligação de eritrócitos
CL2014003605A1 (es)	2015-04-06	Proteínas de fusión de interleuquina-10 y usos de las mismas
DK2920313T3 (da)	2019-09-02	Rekombinante adenovira og anvendelse deraf
CL2015000097A1 (es)	2015-07-10	Agentes de unión de proteína de r-espondina humana (rspo3) y usos de los mismos.
BR112015003149A2 (pt)	2017-08-08	células natural killer e usos das mesmas.
BR112015014063A2 (pt)	2018-10-30	anticorpos anti-b7-h4 humano e seus usos.
CO7071095A2 (es)	2014-09-30	Anticuerpos humanos anti-cd27, métodos, y usos
BR112015002790A2 (pt)	2017-08-08	anticorpos asgpr e usos dos mesmos.
DK2970464T3 (da)	2020-08-03	Anti-lag-3-bindende proteiner
DK3608325T3 (da)	2022-08-22	Polycykliske-carbamoylpyridonforbindelser og deres farmaceutiske anvendelse
DK2850202T3 (da)	2020-05-18	Fremgangsmåder og grupper
DK2925782T3 (da)	2020-04-06	Anti-cd47-antistoffer og fremgangsmåder til anvendelse deraf
BRPI1012340A (pt)	2017-07-25	proteínas de ligação específica e usos das mesmas
CO6801776A2 (es)	2013-11-29	Cosmético
DK2903600T3 (da)	2022-09-26	Virusholdig formulering og anvendelse deraf
DK3431492T3 (da)	2021-03-08	Humane cd30-ligandantigen-bindende proteiner
BR112015011111A2 (pt)	2017-11-14	proteína multifuncional e formulação farmacêutica
BR112014020427A8 (pt)	2018-01-23	polipeptídeos que se ligam ao complemento humano c5
CL2014003372A1 (es)	2015-04-10	Proteinas fijadoras de antigeno antagonistas del receptor de accion dual y sus usos
DK3453723T3 (da)	2021-09-13	Anti-ASIC1-antistoffer og anvendelser deraf
DK3173102T3 (da)	2020-02-24	FGFR-FC-fusionsprotein og anvendelse deraf
DK2834644T3 (da)	2019-11-04	Polymerer, indeholdende multivalente amyloid-beta-bindende d-peptider og deres anvendelse
CL2014002180A1 (es)	2015-04-17	Peptidos antomicrobianos

Legal Events

Date	Code	Title	Description
2018-06-12	B25A	Requested transfer of rights approved	Owner name: IGM BIOSCIENCES A/S (DK)
2019-07-09	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]	Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.
2019-10-08	B25A	Requested transfer of rights approved	Owner name: IGM BIOSCIENCES, INC. (US)
2020-10-06	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-11-03	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2022-12-20	B25G	Requested change of headquarter approved	Owner name: IGM BIOSCIENCES, INC. (US)
2023-01-10	B25A	Requested transfer of rights approved	Owner name: MCURE BIOSCIENCES INC. (US)
2023-03-14	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2023-04-18	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/02/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.